Carbogen Amcis expands operations in Bubendorf
The acquired multi-story building is divided into laboratory, production, storage and office areas and provides a set of cleanroom GMP-compliant suites.
Carbogen Amcis, a Swiss-based company offering process development and manufacturing of APIs to the pharmaceutical industry, has announced the extension of its operations in Bubendorf.
On 26 May 2016, Carbogen Amcis undersigned the acquisition of the land and buildings of GEA Pharma Systems AG in Bubendorf, Hauptstrasse 145. The acquisition, which is close to the company's current headquarters, will become effective on 1 January 2017.
Located on 5200 m² of land, the 3360 m² multi-story building is divided into laboratory, production, storage and office areas and provides a set of cleanroom GMP-compliant suites. The company is planning modification work to adapt the building to its specific requirements and convert more of the facility into GMP operations areas.
“The immediate proximity to our current headquarters and our larger scale production site in Bubendorf, Switzerland, is ideal. It will allow us to significantly extend our laboratory capacity for highly potent development and small scale production as well as analytical support,” said Stephan Fritschi, Vice-President Operations at Carbogen Amcis. “Operations are scheduled to expand into the new building in 2017.”
“In the last couple of years we have experienced a significant and continuous increase in customers’ demand for additional capacity, including demand for labs and small-scale development,” said Mr Janmejay Vyas, Chairman of the Dishman Group of Companies. “This acquisition is targeted to support our business growth and company expansion. It will allow Carbogen Amcis to keep its position as an industry leader and outsourcing partner for complex highly potent APIs and ADCs.”
“I am delighted that we are able to extend our operations in Bubendorf to fulfil our customer needs and their growing expectations,” Commented Mark Griffiths, Global CEO of Carbogen Amcis and the Dishman Group. “Moreover, this facility will bring new opportunities to further enhance our capabilities and capacities. In the near future, the company plans to introduce a number of additional capabilities including, but not limited to, commercial manufacture of ADCs and additional Cat 4 (ng OEL) development capacity. The new facility is closely located with our current Carbogen Amcis Headquarters in Bubendorf and as such enables us to leverage the existing support network to the new site."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance